MIRO insider filings
Miromatrix Medical Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-12-13. Screen MIRO transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for MIRO between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Miromatrix Medical Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-12-13 | 4 | Maag Peter — Director | Code (U): 62,092 · Disposition to issuer (D): 58,368 | EDGAR |
| 2023-12-13 | 4 | Burke William P. Mr. — Director | Code (U): 66,943 · Disposition to issuer (D): 67,413 | EDGAR |
| 2023-12-13 | 4 | Douglas James Michael — CHIEF FINANCIAL OFFICER | Code (U): 31,250 · Disposition to issuer (D): 20,000 · Disposition to issuer (D): 180,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2023-12-13 | 4 | Heine Lisa Wipperman — Director | Code (U): 66,943 · Disposition to issuer (D): 67,413 | EDGAR |
| 2023-12-13 | 4 | Ross Jeffrey James — CHIEF EXECUTIVE OFFICER, Director | Code (U): 308,775 · Disposition to issuer (D): 87,500 · Disposition to issuer (D): 41,250 (derivative) · Disposition to issuer (D): 43,750 (derivative) · Disposition to issuer (D): 33,688 (derivative) · Disposition to issuer (D): 39,375 (derivative) · +5 more | EDGAR |
| 2023-12-13 | 4 | BUCKMAN PAUL — Director | Code (U): 52,593 · Disposition to issuer (D): 54,201 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 18,750 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · +1 more | EDGAR |
| 2023-12-13 | 4 | ERB JOHN L — Director | Code (U): 56,260 · Disposition to issuer (D): 54,201 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 18,750 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · +1 more | EDGAR |
| 2023-06-05 | 4 | Heine Lisa Wipperman — Director | Grant/award (A): 54,201 @ $0 | EDGAR |
| 2023-06-05 | 4 | Burke William P. Mr. — Director | Grant/award (A): 54,201 @ $0 | EDGAR |
| 2023-06-05 | 4 | Maag Peter — Director | Grant/award (A): 54,201 @ $0 | EDGAR |
| 2023-06-05 | 4 | BUCKMAN PAUL — Director | Grant/award (A): 54,201 @ $0 | EDGAR |
| 2023-06-05 | 4 | ERB JOHN L — Director | Grant/award (A): 54,201 @ $0 | EDGAR |
| 2023-03-30 | 4 | Douglas James Michael — CHIEF FINANCIAL OFFICER | Purchase (P): 31,250 @ $1.60 | EDGAR |
| 2023-03-30 | 4 | Ross Jeffrey James — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 31,250 @ $1.60 | EDGAR |
| 2023-03-30 | 4 | Barry John Joseph — VICE PRESIDENT OF R&D | Purchase (P): 6,250 @ $1.60 | EDGAR |
| 2023-03-30 | 4 | Maag Peter — Director | Purchase (P): 31,250 @ $1.60 | EDGAR |
| 2023-03-30 | 4 | Burke William P. Mr. — Director | Purchase (P): 31,250 @ $1.60 | EDGAR |
| 2023-03-30 | 4 | Heine Lisa Wipperman — Director | Purchase (P): 31,250 @ $1.60 | EDGAR |
| 2023-03-30 | 4 | BUCKMAN PAUL — Director | Purchase (P): 31,250 @ $1.60 | EDGAR |
| 2023-03-30 | 4 | ERB JOHN L — Director | Purchase (P): 31,250 @ $1.60 | EDGAR |
| 2023-01-18 | 4 | Ross Jeffrey James — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 50,000 @ $0 · Tax withholding (F): 4,487 @ $3.26 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-01-18 | 4 | Barry John Joseph — VICE PRESIDENT OF R&D | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-01-18 | 4 | Douglas James Michael — CHIEF FINANCIAL OFFICER | Grant/award (A): 20,000 @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-12-08 | 4 | Ross Jeffrey James — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 37,500 @ $1.25 · Tax withholding (F): 11,575 @ $4.05 · Option exercise (M): 37,500 (derivative) @ $0 | EDGAR |
| 2022-10-04 | 4 | Barry John Joseph — VICE PRESIDENT OF R&D | Tax withholding (F): 765 @ $4.38 | EDGAR |
| 2022-08-16 | 4 | Maag Peter — Director | Grant/award (A): 12,788 @ $0 | EDGAR |
| 2022-08-16 | 4 | Heine Lisa Wipperman — Director | Grant/award (A): 12,788 @ $0 | EDGAR |
| 2022-08-16 | 4 | Burke William P. Mr. — Director | Grant/award (A): 12,788 @ $0 | EDGAR |
| 2022-08-16 | 4 | BUCKMAN PAUL — Director | Grant/award (A): 12,788 @ $0 | EDGAR |
| 2022-08-16 | 4 | ERB JOHN L — Director | Grant/award (A): 12,788 @ $0 | EDGAR |
| 2022-03-17 | 4 | Ross Jeffrey James — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 35,438 @ $1.25 · Option exercise (M): 35,438 (derivative) @ $0 | EDGAR |
| 2022-03-02 | 4 | Douglas James Michael — Chief Financial Officer | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Barry John Joseph — VICE PRESIDENT OF R&D | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Kattungal Laji — VICE PRESIDENT OF QUALITY | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Ross Jeffrey James — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4/A | Ross Jeffrey James — CHIEF EXECUTIVE OFFICER, Director | Conversion (C): 4,400 @ $0 · Conversion (C): 4,400 (derivative) | EDGAR |
| 2022-01-18 | 4 | NIEBUR BRIAN — CHIEF FINANCIAL OFFICER | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Ross Jeffrey James — Chief Executive Officer, Director | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Kattungal Laji — Vice President of Quality | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Barry John Joseph — Vice President of R&D | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Heine Lisa Wipperman — Director | Grant/award (A): 4,405 @ $0 · Grant/award (A): 31,712 @ $0 | EDGAR |
| 2022-01-05 | 4 | Burke William P. Mr. — Director | Grant/award (A): 4,405 @ $0 · Grant/award (A): 31,712 @ $0 | EDGAR |
| 2022-01-05 | 4 | NIEBUR BRIAN — Chief Financial Officer | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | Barry John Joseph — Vice President of R&D | Grant/award (A): 10,000 @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | NIEBUR BRIAN — Chief Financial Officer | Grant/award (A): 8,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | NIEBUR BRIAN — Chief Financial Officer | Conversion (C): 3,334 · Conversion (C): 3,334 · Conversion (C): 3,334 (derivative) · Conversion (C): 3,334 (derivative) | EDGAR |
| 2021-06-29 | 4 | BUCKMAN PAUL — Director | Conversion (C): 3,000 · Conversion (C): 3,000 (derivative) | EDGAR |
| 2021-06-29 | 4 | ERB JOHN L — Director | Conversion (C): 6,667 · Conversion (C): 6,667 (derivative) | EDGAR |
| 2021-06-29 | 4 | WAGNER MARK T — Director | Conversion (C): 3,334 · Conversion (C): 3,334 (derivative) | EDGAR |
| 2021-06-29 | 4 | EIBENSTEINER RONALD E — Director | Conversion (C): 59,769 · Conversion (C): 120,000 · Conversion (C): 20,000 · Conversion (C): 59,769 (derivative) · Conversion (C): 20,000 (derivative) · Conversion (C): 120,000 (derivative) | EDGAR |
Recent 8-K events — Miromatrix Medical Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-12-18 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-10-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-06-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MIRO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs